Biologics for Ulcerative Colitis May Decrease Risk for Advanced-Stage Cancer
Researchers sought to determine whether biologic treatment could affect the risk for advanced-stage inflammatory bowel disease-associated intestinal cancer.
Researchers sought to determine whether biologic treatment could affect the risk for advanced-stage inflammatory bowel disease-associated intestinal cancer.
Researchers compared proton pump inhibitors with histamine-2 receptor antagonists to determine if either treatment was associated with risk for IBD.
Researchers examined the relationship between antibiotic use and the development of inflammatory bowel disease in children.
Researchers evaluated the risk for Crohn disease, ulcerative colitis, and IBS in patients with acne starting isotretinoin treatment.
Researchers examined pain medication usage trends before and after initiating advanced therapy in patients newly diagnosed with inflammatory bowel disease.
Adam S. Faye, MD, discusses his team’s research on how antibiotics increase the risk for inflammatory bowel disease among older adults and what clinicians should keep in mind.
Researchers examined the association between micronutrient intake and the risk for ulcerative colitis.
Researchers examined changes in fecal metabolites resulting from either the Crohn disease exclusion diet plus enteral nutrition or the exclusive enteral nutrition diet and the association with remission.
Studies show fecal microbiota transplantation (FMT) can help patients with ulcerative colitis (UC) achieve remission, but challenges must be addressed before FMT can become a standard of treatment for UC.
Researchers evaluated the effects of psychological health on prognosis for inflammatory bowel disease.